Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 459

1.

SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.

Balgkouranidou I, Chimonidou M, Milaki G, Tsaroucha E, Kakolyris S, Georgoulias V, Lianidou E.

Clin Chem Lab Med. 2016 Jan 7. pii: /j/cclm.ahead-of-print/cclm-2015-0776/cclm-2015-0776.xml. doi: 10.1515/cclm-2015-0776. [Epub ahead of print]

PMID:
26741346
2.

The Management and Costs of Locally Advanced or Metastatic Alk-Positive Non-Small Cell Lung Cancer in Greece.

Kousoulakou H, Boukovinas I, Georgoulias V, Kosmidis P, Koumakis G, Makrantonakis P, Samantas E, Syrigos K, Krikelis D, Markouri A, Geitona M.

Value Health. 2015 Nov;18(7):A451. doi: 10.1016/j.jval.2015.09.1138. Epub 2015 Oct 20. No abstract available.

PMID:
26532537
3.

Palliative chemotherapy for patients with breast cancer.

Saloustros E, Georgoulias V.

Lancet Oncol. 2015 Nov;16(15):1453-4. doi: 10.1016/S1470-2045(15)00399-X. Epub 2015 Oct 22. No abstract available.

PMID:
26482276
4.

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.

Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V.

Breast Cancer Res. 2015 Aug 19;17:113. doi: 10.1186/s13058-015-0624-x.

5.

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.

Kourlaba G, Rapti V, Alexopoulos A, Relakis J, Koumakis G, Chatzikou M, Maniadakis N, Georgoulias V.

BMC Health Serv Res. 2015 Aug 5;15:307. doi: 10.1186/s12913-015-0971-4.

6.

Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway.

Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D.

BMC Cancer. 2015 Jul 24;15:542. doi: 10.1186/s12885-015-1562-9.

7.

Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.

Syrios J, Nintos G, Georgoulias V.

Expert Rev Anticancer Ther. 2015 Aug;15(8):875-84. doi: 10.1586/14737140.2015.1069186.

PMID:
26204906
8.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators.

Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.

PMID:
26156651
9.

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.

Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V.

PLoS One. 2015 Jun 17;10(6):e0123683. doi: 10.1371/journal.pone.0123683. eCollection 2015.

10.

Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.

Koinis F, Nintos G, Georgoulias V, Kotsakis A.

Expert Opin Pharmacother. 2015;16(10):1505-19. doi: 10.1517/14656566.2015.1055248. Epub 2015 Jun 16. Review.

PMID:
26077189
11.

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

O'Brien ME, Gaafar R, Hasan B, Menis J, Cufer T, Popat S, Woll PJ, Surmont V, Georgoulias V, Montes A, Blackhall F, Hennig I, Schmid-Bindert G, Baas P; EORTC-LCG.

Eur J Cancer. 2015 Aug;51(12):1511-28. doi: 10.1016/j.ejca.2015.04.026. Epub 2015 Jun 11.

PMID:
26074395
12.

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.

Polioudaki H, Agelaki S, Chiotaki R, Politaki E, Mavroudis D, Matikas A, Georgoulias V, Theodoropoulos PA.

BMC Cancer. 2015 May 13;15:399. doi: 10.1186/s12885-015-1386-7.

13.

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece.

Ann Oncol. 2015 Jul;26(7):1333-40. doi: 10.1093/annonc/mdv213. Epub 2015 May 1.

PMID:
25935793
14.

The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer.

Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J.

Cancers (Basel). 2015 Mar 13;7(1):439-49. doi: 10.3390/cancers7010439. Review.

15.

A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples.

Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Chim Acta. 2015 Apr 15;444:303-9. doi: 10.1016/j.cca.2015.02.035. Epub 2015 Feb 27.

PMID:
25727515
16.

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7. doi: 10.1007/s00280-015-2707-x. Epub 2015 Feb 22.

PMID:
25702051
17.

Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs.

Matikas A, Mistriotis D, Georgoulias V, Kotsakis A.

Clin Lung Cancer. 2015 Jul;16(4):252-61. doi: 10.1016/j.cllc.2014.12.013. Epub 2015 Jan 8. Review.

PMID:
25700775
18.

Metastasis-related miRNAs: a new way to differentiate patients with higher risk?

Markou A, Lianidou E, Georgoulias V.

Future Oncol. 2015;11(3):365-7. doi: 10.2217/fon.14.294. No abstract available.

19.

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).

Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V.

Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23.

PMID:
25662596
20.

ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, Mavroudis D, Georgoulias V.

Cancer Invest. 2015 Apr;33(4):107-13. doi: 10.3109/07357907.2014.1001897. Epub 2015 Feb 3.

PMID:
25647444
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk